Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been assigned an average recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.88.

A number of research analysts have commented on the company. Canaccord Genuity Group restated a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Piper Sandler assumed coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target on the stock. Finally, Chardan Capital upped their price target on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, March 21st.

Taysha Gene Therapies Trading Down 5.8 %

TSHA opened at $2.27 on Friday. Taysha Gene Therapies has a one year low of $0.50 and a one year high of $3.89. The stock has a market capitalization of $424.54 million, a PE ratio of -3.39 and a beta of 0.29. The business’s 50 day moving average price is $2.56 and its 200 day moving average price is $2.10. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. As a group, equities research analysts expect that Taysha Gene Therapies will post -0.39 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently modified their holdings of TSHA. Swiss National Bank raised its stake in shares of Taysha Gene Therapies by 9.3% in the first quarter. Swiss National Bank now owns 41,000 shares of the company’s stock valued at $267,000 after acquiring an additional 3,500 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Taysha Gene Therapies by 85.1% in the first quarter. JPMorgan Chase & Co. now owns 439,804 shares of the company’s stock valued at $2,868,000 after acquiring an additional 202,245 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 14.5% in the first quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company’s stock valued at $6,599,000 after acquiring an additional 128,517 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Taysha Gene Therapies in the first quarter valued at $1,633,000. Finally, UBS Group AG increased its holdings in Taysha Gene Therapies by 33.2% in the first quarter. UBS Group AG now owns 67,980 shares of the company’s stock valued at $443,000 after buying an additional 16,944 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.